9
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T12428L | PF-06726304 | Histone Methyltransferase | |
PF-06726304 shows robust antitumor growth activity. PF-06726304 is an effective and selective EZH2 inhibitor. PF-06726304 inhibits wild-type and Y641N mutant EZH2 (Kis: 0.7 and 3.0 nM, respectively). | |||
T6809 | CPI-169 racemate | CPI 169,CPI-169,CPI169 | Epigenetic Reader Domain , Histone Methyltransferase |
CPI-169 racemate (CPI 169) is a potent, and selective EZH2 inhibitor with IC50 of 0.24 nM, 0.51 nM, and 6.1 nM for EZH2 WT, EZH2 Y641N, and EZH1, respectively. | |||
T12430 | PF-06821497 | Histone Methyltransferase | |
PF-06821497 is a selective inhibitor of EZH2 with significant tumor growth inhibition. | |||
T79780 | IHMT-EZH2-426 | Histone Methyltransferase | |
IHMT-EZH2-426 (compound 38) is a potent, covalent degrader of EZH2, demonstrating IC50 values of 1.3 nM for EZH2 wild-type, 1.2 nM for EZH2-A687V, and 1.7-3.5 nM for EZH2-Y641F/Y641N/Y641S mutants. The compound effective... | |||
T73246 | EZH2-IN-7 | ||
EZH2-IN-7, a potent inhibitor of EZH2, addresses overexpression or mutations in the SET region (Y641F, Y641N, A687V, A677G point mutations) that cause an abnormal increase in H3K27me3, contributing to the proliferation o... | |||
T64208 | EZH2-IN-9 | ||
EZH2-IN-9 is a potent inhibitor of EZH2, whose overexpression or mutations in the SET region (Y641F, Y641N, A687V, A677G point mutations) cause abnormal elevations in H3K27me3 and contribute to the growth and development... | |||
T64307 | EZH2-IN-8 | ||
EZH2-IN-8 is a potent inhibitor of EZH2. EZH2-IN-8 has the potential to be used in the study of cancer diseases. | |||
T12428 | PF-06726304 acetate | Histone Methyltransferase | |
PF-06726304 acetate is a selective inhibitor of EZH2, with robust antitumor growth activity. | |||
T27069 | CPI-169 | CPI 169 (R),CPI-169 (R) | |
CPI-169 (R) is a novel and potent inhibitor of EZH2. |